TapImmune Provides Update on PolyStart™ Vaccine Platform Applicable to Cancer and Infectious Disease Print E-mail
Wednesday, 22 October 2014 22:39
SEATTLE, WASHINGTON--TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM  vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
Read more...
 
Newsmakers: MELA Sciences, Synergy Pharmaceuticals, Omeros, Novartis, Enanta Pharmaceuticals Print E-mail
Tuesday, 21 October 2014 15:10
U.S. stocks rallied on Tuesday, with the S&P 500 on track for a fourth straight session of gains boosted by strong corporate results, including Apple's.
Read more...
 
Movers: Tetraphase Pharmaceuticals, Repros Therapeutics, Horizon Pharma, Theravance Inc, Myriad Genetics Print E-mail
Friday, 17 October 2014 15:02
U.S. stocks rallied Friday, extending a string of sharp moves, amid upbeat economic news from the U.S. and rising hopes for more stimulus from global central banks.
Read more...
 
PROVECTUS’ INTRALESIONAL PV-10 CLINICAL DATA TO BE PRESENTED TO THE 2014 INTERNATIONAL CONGRESS OF THE SOCIETY FOR MELANOMA RESEARCH Print E-mail
Thursday, 16 October 2014 18:07
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.
Read more...
 
RELMADA THERAPEUTICS REINFORCES BALANCE SHEET WITH $15.2 MILLION FROM EXERCISE OF WARRANTS Print E-mail
Thursday, 16 October 2014 18:04
New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014.
Read more...
 
Newsmakers: GeoVax Labs, Orexigen Therapeutics, Luminex, Navidea Biopharmaceuticals, Alexion Pharmaceuticals Print E-mail
Wednesday, 15 October 2014 14:36
Stocks suffered their biggest losses in years and the dollar slumped on Wednesday after the latest inflation data from the United States and China fanned worries about a global slowdown, driving investors into safe-haven government debt.
Read more...
 
Movers: Galena Biopharma, AEterna Zentaris, Med-Cannabis Pharma, Exactech, Retrophin Print E-mail
Tuesday, 14 October 2014 14:14
U.S. stocks climbed in afternoon trading on Tuesday, with the S&P 500 recovering from a three-day string of losses that was its worst since November 2011.
Read more...
 
INC RESEARCH SIGNS AGREEMENT TO PERFORM FDA DUE DILIGENCE AUDIT OF REGULATORY DOCUMENTS FOR PROVECTUS BIOPHARMACEUTICALS Print E-mail
Tuesday, 14 October 2014 13:57
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it has retained INC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.
Read more...
 
Newsmakers: Gilead Sciences, AstraZeneca, Aastrom Biosciences, Exact Sciences, Lakeland Industries Print E-mail
Friday, 10 October 2014 16:06
U.S. stock indexes drifted mostly higher in afternoon trading Friday, paring back earlier losses but still on track to end lower for the week.
Read more...
 
Movers: Ocean Bio-Chem, Regen BioPharma, Arrowhead Research, Unilife, Salix Pharmaceuticals Print E-mail
Wednesday, 08 October 2014 14:11
U.S. stocks extended gains as investors speculated the Federal Reserve would keep interest rates lower for longer on concern that a global slowdown will hurt the American economy.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 8 of 12

Newsletter